InsiderTrades.com logo
These AI trades triggered this morning (545% return)
From Prosper Trading Academy   |   Ad
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Click Here To Get Your Free Copy

Calvin Roberts Biography and Net Worth

Director of IVERIC bio
  • Phone
  • Email
  • Website


Dr. Calvin W. Roberts M.D. serves as Independent Director of the Company. He has served as a member of our board of directors since January 2019. Dr. Roberts has served as president and chief executive officer of the Lighthouse Guild since April 2020. Previously, he served as the senior vice president, chief medical officer of Eye Care at Bausch Health Companies Inc., a publicly traded pharmaceutical company, from March 2011 to March 2020. Since 1982, Dr. Roberts has also served as a clinical professor of ophthalmology at Weill Cornell Medical College and was a practicing ophthalmologist for over 26 years. Dr. Roberts is a renowned specialist in cataract and refractive surgery. Dr. Roberts previously served as a consultant for Allergan, Inc., Johnson & Johnson, and Novartis AG. Dr. Roberts currently serves on the board of directors of Auris Medical Holding AG and previously served on the board of directors of Alimera Sciences, Inc., both publicly-traded biotechnology companies. Dr. Roberts received an A.B. from Princeton University and an M.D. from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital, and cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts holds patents on a number of devices used for ophthalmic surgery. Roberts is qualified to serve on our board of directors because of his extensive experience in the opthalmology field, both as a practitioner and as a senior industry executive.

What is Calvin W. Roberts' net worth?

The estimated net worth of Calvin W. Roberts is at least $1.30 million as of June 13th, 2022. Dr. Roberts owns 32,500 shares of IVERIC bio stock worth more than $1,298,375 as of April 27th. This net worth evaluation does not reflect any other assets that Dr. Roberts may own. Learn More about Calvin W. Roberts' net worth.

How do I contact Calvin W. Roberts?

The corporate mailing address for Dr. Roberts and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at [email protected]. Learn More on Calvin W. Roberts' contact information.

Has Calvin W. Roberts been buying or selling shares of IVERIC bio?

Calvin W. Roberts has not been actively trading shares of IVERIC bio during the last ninety days. Most recently, on Monday, June 13th, Calvin W. Roberts bought 25,000 shares of IVERIC bio stock. The stock was acquired at an average cost of $9.62 per share, with a total value of $240,500.00. Following the completion of the transaction, the director now directly owns 32,500 shares of the company's stock, valued at $312,650. Learn More on Calvin W. Roberts' trading history.

Who are IVERIC bio's active insiders?

IVERIC bio's insider roster includes David Carroll (CFO), Pravin Dugel (EVP), Anthony Gibney (EVP), Calvin Roberts (Director), Glenn Sblendorio (CEO), Christopher Simms (SVP), and Keith Westby (COO). Learn More on IVERIC bio's active insiders.

Are insiders buying or selling shares of IVERIC bio?

During the last year, insiders at the sold shares 4 times. They sold a total of 123,500 shares worth more than $4,640,840.00. The most recent insider tranaction occured on July, 3rd when COO Keith Westby sold 20,000 shares worth more than $789,000.00. Insiders at IVERIC bio own 2.7% of the company. Learn More about insider trades at IVERIC bio.

Information on this page was last updated on 7/3/2023.

Calvin W. Roberts Insider Trading History at IVERIC bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/13/2022Buy25,000$9.62$240,500.0032,500View SEC Filing Icon  
See Full Table

Calvin W. Roberts Buying and Selling Activity at IVERIC bio

This chart shows Calvin W Roberts's buying and selling at IVERIC bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IVERIC bio Company Overview

IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
Read More

Today's Range

Now: $39.95
Low: $39.95
High: $39.95

50 Day Range

MA: $38.88
Low: $36.90
High: $39.95

2 Week Range

Now: $39.95
Low: $9.39
High: $39.99

Volume

N/A

Average Volume

3,616,141 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06
These AI trades triggered this morning (545% return)
From Prosper Trading Academy   |   Ad
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Click Here To Get Your Free Copy